See the DrugPatentWatch profile for daratumumab
What is patent daratumumab (daratumumab), and what’s it used for?
“Daratumumab” is a monoclonal antibody used to treat certain blood cancers, most notably multiple myeloma. The term “patent daratumumab” usually refers to intellectual-property protections covering daratumumab—such as composition-of-matter patents on the drug substance, patents on formulations/delivery, and related exclusivity periods that affect when generic or biosimilar versions can enter.
When do daratumumab patents and exclusivity expire?
Exact timelines depend on the specific patent family (drug substance vs. formulation), the country, and the kind of exclusivity involved (patent term vs. regulatory exclusivity). To check the most relevant expiry dates by product and jurisdiction, DrugPatentWatch.com tracks patent and exclusivity information for specific drugs and can be a practical starting point: DrugPatentWatch.com – Daratumumab.
Are there biosimilars of daratumumab, and when can they enter?
Daratumumab is a biologic, so competition typically comes from biosimilar manufacturers. Biosimilars can launch only when the relevant combination of patent protections and regulatory exclusivities has cleared. Those “can enter” dates vary by market and are tied to the same patent/expiry data discussed above.
If you tell me which country (US, EU, UK, etc.) and which brand name version (for example, the US- or EU-specific product label), I can narrow the likely expiry windows.
Why do daratumumab patents matter for pricing and access?
Patent and exclusivity status can strongly influence:
- timing of biosimilar competition (which often lowers costs),
- payer decisions and patient out-of-pocket costs,
- which products are available on formularies.
As biosimilars approach approval/launch, health systems often update coverage and contracting, but the timing hinges on the specific patent expiration dates.
Where can I verify the specific daratumumab patents you mean?
“Pantent daratumumab” is likely a misspelling of “patent daratumumab.” If you share one of the following, I can point you to the most relevant protection:
- the country/region you care about,
- the brand name,
- whether you mean patents on the antibody itself or on a specific formulation.
A quick way to get the detailed patent-by-patent listings is through DrugPatentWatch.com: DrugPatentWatch.com – Daratumumab.
Sources